MyEllevate is the first and only patented light-guided technology for use in soft tissue approximation and the elevation of sub dermis and underlying muscle.
Cynosure is acquiring the MyEllevate Surgical Suture System, which allows practitioners to place a suture support system without incisions.
MyEllevate, performed with the ICLED light-guided suture system, is the first and only patented light-guided technology for use in soft tissue approximation and the elevation of sub dermis and underlying muscle. This one-time use disposable surgical kit enables the placement of a suture support system through a series of guided needle punctures for a less invasive approach. It can be performed under local anesthesia in a surgeon’s office and can be used as a stand-alone procedure or in combination with other treatments such as TempSure Surgical or SmartLipo laser lipolysis treatments and energy-based skin tightening.
The news was announced at The Aesthetic Society’s “The Aesthetic Meeting 2021.”
“Acquiring MyEllevate will broaden Cynosure’s already extensive surgical product portfolio, enabling us to offer this ground-breaking procedure in combination with other energy-based skin tightening technologies for optimal, long-lasting results,” says Todd Tillemans, Chief Executive Officer of Cynosure, in a news release. “Also known as the Zoom Lift, MyEllevate has gained popularity recently as more patients look for minimally invasive solutions to improve their appearance in today’s world of virtual meetings.”
“We are very excited to join forces with a company at the forefront of beauty aesthetic innovation that prioritizes both patient outcomes and customer satisfaction,” adds Dr. Gregory Mueller, MD, FACS Board-Certified Plastic Surgeon and Inventor of the MyEllevate System. “As procedures like neck and face lifts continue to decline in popularity due to their invasiveness and extensive recovery time, patients are seeking new and innovative options.”
“The innovative MyEllevate System expands our global commitment to minimally invasive surgical treatments, delivers on a key unmet consumer need and delivers optimal patient outcomes,” says Sandi Peterson, Clayton, Dubilier & Rice Operating Partner and Chairman of the Board of Cynosure.
